» Articles » PMID: 29907790

Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats - Improving Yield and Reproducibility

Overview
Journal Sci Rep
Specialty Science
Date 2018 Jun 17
PMID 29907790
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being a cardinal experimental model, the induction of cirrhosis in rats by repeated exposure to carbon tetrachloride (CCl4) has low reproducibility. Here, we compared two models of cirrhosis induced by orogastric administration of CCl4 once (CCl4-1xWk) or twice a week (CCl4-2xWk) for 12 weeks in male Sprague-Dawley rats. Control rats received water instead of CCl4. Both CCl4 protocols similarly attenuated body weight gain (p < 0.01 vs. Control). Although both CCl4 protocols increased hepatic fibrosis, portal hypertension and splenomegaly, the magnitude of these alterations was higher and more consistent in CCl4-2xWk rats. Importantly, two CCl4-1xWk rats did not develop cirrhosis versus a 100% yield of cirrhosis in CCl4-2xWk rats. The CCl4-2xWk protocol consistently induced liver atrophy together with hematological, biochemical and coagulation abnormalities characteristic of advanced cirrhosis that were absent in CCl4-1xWk rats. Ascites occurred in 20% and 80% of rats in theCCl4-1xWk and CCl4-2xWk groups (p < 0.01). All rats showed normal renal function, arterial blood gases and stable systemic hemodynamics. The total dose of CCl4 and mortality rate were similar in both protocols. The CCl4-2xWk protocol, therefore, was highly reproducible and effective for the induction of experimental cirrhosis within a confined time, representing a valuable advance for liver research.

Citing Articles

Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice.

Abdelsalam M, El-Mahdy N, Abou-Saif S Liver Res. 2025; 7(1):71-81.

PMID: 39959700 PMC: 11791913. DOI: 10.1016/j.livres.2023.02.001.


New insight on the acute CCl-induced hepatotoxicity model in rats.

Dos Anjos Melo D, Silva M, de Oliveira N, de Oliveira Neto J, de Souza Lino Junior R, Cruz A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39878816 DOI: 10.1007/s00210-025-03824-6.


In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration.

Hu Y, Zhang Z, Adiham A, Li H, Gu J, Gong P Int J Mol Sci. 2025; 26(2).

PMID: 39859410 PMC: 11766297. DOI: 10.3390/ijms26020696.


Resveratrol treatment ameliorates hepatic damage via the TGF-β/SMAD signaling pathway in a phenobarbital/CCl-induced hepatic fibrosis model.

Aykac M, Balkan E, Gedi Kli S, Ozturk N Iran J Basic Med Sci. 2024; 27(9):1124-1133.

PMID: 39055873 PMC: 11266736. DOI: 10.22038/IJBMS.2024.75737.16398.


Label-free proteomic analysis reveals the hepatoprotective mechanism of gypenosides in liver injury rats.

Chen Y, Ma L, Wang Y, Zhang J, Pei T, Wang M Front Pharmacol. 2024; 15:1417575.

PMID: 38994199 PMC: 11236725. DOI: 10.3389/fphar.2024.1417575.


References
1.
Abraldes J, Pasarin M, Garcia-Pagan J . Animal models of portal hypertension. World J Gastroenterol. 2006; 12(41):6577-84. PMC: 4125660. DOI: 10.3748/wjg.v12.i41.6577. View

2.
Runyon B, Sugano S, Kanel G, Mellencamp M . A rodent model of cirrhosis, ascites, and bacterial peritonitis. Gastroenterology. 1991; 100(2):489-93. DOI: 10.1016/0016-5085(91)90221-6. View

3.
Llovet J, Bartoli R, Planas R, Cabre E, Jimenez M, Urban A . Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut. 1994; 35(11):1648-52. PMC: 1375630. DOI: 10.1136/gut.35.11.1648. View

4.
. 12th Report on Carcinogens. Rep Carcinog. 2011; 12. View

5.
Wang Y, Wang S, Bickel M, Guenzler V, Gerl M, BISSELL D . Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol. 1998; 152(1):279-87. PMC: 1858123. View